AU2015358493B2 - Anticancer compositions - Google Patents

Anticancer compositions Download PDF

Info

Publication number
AU2015358493B2
AU2015358493B2 AU2015358493A AU2015358493A AU2015358493B2 AU 2015358493 B2 AU2015358493 B2 AU 2015358493B2 AU 2015358493 A AU2015358493 A AU 2015358493A AU 2015358493 A AU2015358493 A AU 2015358493A AU 2015358493 B2 AU2015358493 B2 AU 2015358493B2
Authority
AU
Australia
Prior art keywords
arn
solid dispersion
poly
meth
acrylate copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015358493A
Other languages
English (en)
Other versions
AU2015358493A1 (en
Inventor
Geert Verreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aragon Pharmaceuticals Inc
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015358493(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of AU2015358493A1 publication Critical patent/AU2015358493A1/en
Application granted granted Critical
Publication of AU2015358493B2 publication Critical patent/AU2015358493B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015358493A 2014-12-05 2015-12-03 Anticancer compositions Active AU2015358493B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05
EP14196591.3 2014-12-05
PCT/US2015/063667 WO2016090101A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (2)

Publication Number Publication Date
AU2015358493A1 AU2015358493A1 (en) 2017-06-08
AU2015358493B2 true AU2015358493B2 (en) 2021-05-06

Family

ID=52006905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015358493A Active AU2015358493B2 (en) 2014-12-05 2015-12-03 Anticancer compositions

Country Status (31)

Country Link
US (3) US20170360707A1 (OSRAM)
EP (2) EP3842034B1 (OSRAM)
JP (1) JP6767368B2 (OSRAM)
KR (1) KR102348325B1 (OSRAM)
CN (2) CN106999430A (OSRAM)
AR (1) AR102924A1 (OSRAM)
AU (1) AU2015358493B2 (OSRAM)
CA (1) CA2969661C (OSRAM)
CL (1) CL2017001372A1 (OSRAM)
CO (1) CO2017005573A2 (OSRAM)
CR (1) CR20170217A (OSRAM)
CY (1) CY1123856T1 (OSRAM)
DK (1) DK3226842T3 (OSRAM)
EA (1) EA035988B1 (OSRAM)
ES (2) ES3021508T3 (OSRAM)
HR (1) HRP20201902T1 (OSRAM)
HU (1) HUE051888T2 (OSRAM)
IL (1) IL252324B (OSRAM)
LT (1) LT3226842T (OSRAM)
MA (2) MA55404A (OSRAM)
MD (1) MD3226842T2 (OSRAM)
MX (1) MX384382B (OSRAM)
NI (1) NI201700069A (OSRAM)
PL (1) PL3226842T3 (OSRAM)
PT (1) PT3226842T (OSRAM)
RS (1) RS61466B1 (OSRAM)
SG (1) SG11201704264UA (OSRAM)
SI (1) SI3226842T1 (OSRAM)
TW (1) TWI683662B (OSRAM)
UA (1) UA121123C2 (OSRAM)
WO (1) WO2016090101A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
MA41107B1 (fr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals, Inc. Compositions anti-cancéreuses
LT3226843T (lt) 2014-12-05 2021-08-10 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
JP7244536B2 (ja) * 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
PH12021551657A1 (en) 2019-01-30 2022-05-02 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
CN113711316A (zh) 2019-01-30 2021-11-26 詹森药业有限公司 基于分子亚型治疗前列腺癌的方法
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
JP2023500935A (ja) 2019-11-04 2023-01-11 アラゴン ファーマシューティカルズ，インコーポレイテッド 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
AU2024236119A1 (en) 2023-03-16 2025-09-25 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023710A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080902A1 (en) 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
WO2005055987A1 (en) * 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER
LT2656841T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2721003B1 (en) * 2011-06-15 2018-01-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US9481663B2 (en) 2012-06-07 2016-11-01 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
ES2892029T3 (es) * 2012-09-11 2022-02-01 Medivation Prostate Therapeutics Llc Formulaciones de enzalutamida
UA117663C2 (uk) * 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
BR112015015758B1 (pt) * 2013-01-22 2022-01-04 F. Hoffmann-La Roche Ag Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
EP3102183A1 (en) * 2014-02-05 2016-12-14 LEK Pharmaceuticals d.d. Solid pharmaceutical compositions of androgen receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023710A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

Also Published As

Publication number Publication date
UA121123C2 (uk) 2020-04-10
CA2969661A1 (en) 2016-06-09
MA55404A (fr) 2022-02-02
ES2839128T3 (es) 2021-07-05
MA41108B1 (fr) 2021-03-31
TW201632187A (zh) 2016-09-16
US20170360707A1 (en) 2017-12-21
WO2016090101A1 (en) 2016-06-09
EP3226842A1 (en) 2017-10-11
PL3226842T3 (pl) 2021-07-12
TWI683662B (zh) 2020-02-01
BR112017011787A2 (pt) 2017-12-26
MD3226842T2 (ro) 2021-03-31
AU2015358493A1 (en) 2017-06-08
KR20170086657A (ko) 2017-07-26
KR102348325B1 (ko) 2022-01-06
PT3226842T (pt) 2020-12-23
CN115837010A (zh) 2023-03-24
NI201700069A (es) 2017-10-31
IL252324B (en) 2021-10-31
HRP20201902T1 (hr) 2021-07-23
CN115837010B (zh) 2025-03-14
EP3842034A1 (en) 2021-06-30
CA2969661C (en) 2023-04-25
MX2017007201A (es) 2018-01-30
MA41108A (fr) 2016-06-09
RS61466B1 (sr) 2021-03-31
US20240293321A1 (en) 2024-09-05
CY1123856T1 (el) 2022-05-27
ES3021508T3 (en) 2025-05-27
JP2017536401A (ja) 2017-12-07
EA035988B1 (ru) 2020-09-09
SI3226842T1 (sl) 2021-04-30
LT3226842T (lt) 2021-03-25
CO2017005573A2 (es) 2017-09-29
US20220151931A1 (en) 2022-05-19
EP3226842B1 (en) 2020-11-25
CN106999430A (zh) 2017-08-01
CR20170217A (es) 2017-08-30
DK3226842T3 (da) 2021-01-25
EA201791252A1 (ru) 2017-10-31
EP3842034B1 (en) 2025-02-12
AR102924A1 (es) 2017-04-05
SG11201704264UA (en) 2017-06-29
MX384382B (es) 2025-03-14
IL252324A0 (en) 2017-07-31
HUE051888T2 (hu) 2021-03-29
JP6767368B2 (ja) 2020-10-14
CL2017001372A1 (es) 2018-01-05

Similar Documents

Publication Publication Date Title
US12303493B2 (en) Anticancer compositions
US20240293321A1 (en) Anticancer compositions
US20190216829A1 (en) Anticancer Compositions
HK40055486A (en) Anticancer compositions
HK40078336A (en) Anticancer compositions
HK1241764B (en) Anticancer compositions
HK1241764A1 (en) Anticancer compositions
HK1241758A1 (en) Anticancer compositions
EA043321B1 (ru) Противораковая композиция
BR112017011787B1 (pt) Dispersão sólida, seu processo de preparação, partícula, formulação farmacêutica, uso da dita formulação e combinação

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)